Datavault AI investors urged to act before Oct 5 class action deadline
- Rosen Law Firm urges Datavault AI investors to act before Oct 5, 2026, lead plaintiff deadline
- Lawsuit alleges false statements on partnerships and trading volume from Sept 4, 2024, to Oct 30, 2025
- Core claims include overstated Scilex and Nature’s Miracle deals and minimal platform activity
- Insiders sold 38 million shares worth over $73.8 million during the class period
- Stock fell 19.44% to $2.03 following Wolfpack Research report

*this image is generated using AI for illustrative purposes only.
The Rosen Law Firm and other legal groups are urging Datavault AI Inc. (NASDAQ: DVLT) investors to secure counsel ahead of the October 5, 2026, deadline for lead plaintiff status in a pending securities class action. The lawsuit alleges the company made materially false statements regarding partnership values and platform trading volume between September 4, 2024, and October 30, 2025.
The class action, filed in the United States District Court for the Eastern District of Pennsylvania, covers the period from September 4, 2024, to October 30, 2025. Investors who purchased Datavault AI securities during this window may be entitled to compensation under a contingency fee arrangement. The legal coalition includes Robbins LLP, Glancy Prongay Wolke & Rotter LLP, the Law Offices of Howard G. Smith, Levi & Korsinsky LLP, Bragar Eagel & Squire, P.C., The Law Offices of Frank R. Cruz, and The Rosen Law Firm.
Core Allegations and Financial Discrepancies
The lawsuit alleges that Datavault AI and certain officers violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 by overstating the economic value of partnerships with Burke Products, Scilex Holding Company, and Nature’s Miracle Holding Inc. Plaintiffs assert the company exaggerated trading volume on its Datavault Platform and concealed connections between leadership and Edward Withrow III, a convicted felon.
A central allegation concerns the Datavault Platform, described as a flagship property acquired in a $210 million intellectual property transaction. While the company claimed a 30% cut of each trade, plaintiffs allege trading activity was minimal. A Wolfpack Research report published on October 31, 2025, stated that trading activity appeared to be "minimal, if not non-existent," consisting largely of low-value tokens.
| Partnership | Announced Value/Claim | Alleged Actual Financials | Discrepancy Detail |
|---|---|---|---|
| Scilex Holding Company | $150 million strategic investment | $4.1 million cash and equivalents | Alleged lack of funds to fulfill investment promise. |
| Nature’s Miracle | $2 million non-refundable license fee | $9,511 cash | Alleged inability to pay license fee based on reported cash. |
| Burke Products | Defense sector positioning ($900B budget context) | ~$3.1 million awards (2025) | Alleged overstatement of contract scale and significance. |
| Datavault Platform | High trading volume implied | Minimal to non-existent activity | Alleged exaggeration of platform utility and usage. |
Chronology of Material Events
The complaint outlines a sequence of announcements that plaintiffs argue misled investors about the company’s commercial substance:
- September 4, 2024: Announcement of a $210 million Data Vault Holdings IP acquisition. The complaint alleges this announcement omitted prior SEC charges against the incoming chief executive and his patent co-inventor’s felony conviction for false statements tied to a pump and dump scheme.
- February 13, 2025: Company name changed from WiSA Technologies to Datavault AI.
- July 9, 2025: A $250 million shelf registration statement declared effective by the SEC.
- July 22, 2025: Burke Products partnership announced as delivering 2025 revenues from subcontracted existing contracts, citing a U.S. defense budget expected to surpass $900 billion.
- September 25, 2025: A $150 million strategic investment from Scilex Holding Company announced, structured in tranches of $8,067,000 and $141,933,000.
- October 28, 2025: Nature’s Miracle license announced with a $2 million non-refundable fee and a 35 percent royalty.
- October 31, 2025: Wolfpack Research report published; shares closed at $2.03.
Leadership Disclosure Allegations
New filings emphasize allegations that management omitted material risks regarding leadership background. The lawsuit asserts that when the company announced its incoming chief executive in September 2024, management touted an "exceptional track record" while omitting that the individual had previously faced SEC charges for making false statements as an officer of a health sciences issuer. Those charges were resolved through a $40,000 fine and a three-year ban from participating in penny stock offerings.
Additionally, the complaint alleges undisclosed affiliations in the patent portfolio. An individual listed as a co-inventor alongside company leadership on multiple acquired patents had previously pleaded guilty to making false statements in connection with a pump and dump scheme. According to the complaint, Datavault failed to disclose this affiliation to investors.
Counsel Selection and Firm Track Record
Robbins LLP highlighted its role in shareholder rights litigation, noting it has helped restore more than $1 billion in value to shareholders. Attorney Aaron Dumas, Jr., handles the case for Robbins LLP, while Charles Linehan, Esq., leads the effort for Glancy Prongay Wolke & Rotter LLP. Both firms represent investors on a contingency fee basis.
Levi & Korsinsky LLP, led by Joseph E. Levi, Esq., highlighted its status as a Top 50 securities litigation firm by ISS for seven consecutive years. The firm noted that institutions with the largest documented losses are typically best positioned for lead plaintiff consideration. Joseph E. Levi can be contacted at jlevi@levikorsinsky.com or (212) 363-7500.
The Law Offices of Frank R. Cruz, based in Los Angeles, also reminded investors of the upcoming deadline. Frank R. Cruz can be contacted at 310-914-5007 or via email at info@frankcruzlaw.com .
The Rosen Law Firm, led by Phillip Kim, Esq., encouraged investors with losses exceeding $100,000 to contact the firm. Rosen Law emphasized its global practice in securities class actions and shareholder derivative litigation, noting it was ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017 and has been ranked in the top 4 each year since 2013. The firm recovered over $438 million for investors in 2019 alone. Founding partner Laurence Rosen was named a Titan of Plaintiffs' Bar by law360 in 2020. Investors are advised to select qualified counsel with a track record of success, as some firms issuing notices may merely refer clients rather than litigate cases.
Insider Activity and Market Impact
According to the complaint, insiders sold 38,065,752 shares worth over $73.8 million during the Class Period. Following the Wolfpack Research report, Datavault AI’s stock price fell $0.49 per share, or 19.44%, to close at $2.03 per share on October 31, 2025. Investors are reminded that no class has been certified and they are not represented by counsel unless they retain one.
How might the outcome of the lead plaintiff selection process influence the litigation strategy and potential settlement value for Datavault AI investors?
What are the implications of the alleged undisclosed leadership backgrounds and patent co-inventor affiliations on the company's corporate governance reforms and future executive appointments?
Could the allegations regarding minimal trading volume on the Datavault Platform trigger a broader regulatory review of similar AI-driven trading platforms and their reporting standards?

































